Pfizer and Biohaven bring rimegepant to Europe as migraine war with AbbVie heats up

AbbVie’s been cranking up the heat on Biohaven’s oral migraine med Nurtec with its rival Qulipta. Biohaven’s solution? Take the competition overseas.

Nurtec — or rimegepant, as it’s known chemically — is now the first drug approved in the EU for both acute and prophylactic treatment of migraines, where it...

Click to view original post